Physician profile
Fredrick Baker
NPI 1346248416
$2,584.15
in general payments reported to CMS, 2019-2025
23 companies · $18.42 in 2025
The $18.42 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,383 · 2020: $999 · 2021: $22.43 · 2022: $31.86 · 2023: $14.31 · 2024: $115 · 2025: $18.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $363.94 | 2019-2020 | |
| Amgen INC. | $353.48 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $295.70 | 2019-2020 | |
| Pfizer INC. | $236.01 | 2019-2023 | |
| Lilly USA, LLC | $212.93 | 2019-2025 | Kisunla, Mounjaro |
| Merck Sharp & Dohme LLC | $190.46 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.89 | 2019-2020 | |
| Glaxosmithkline, LLC. | $137.58 | 2019-2020 | |
| Amarin Pharma, INC. | $126.46 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $97.27 | 2019-2020 | |
| Daiichi Sankyo INC. | $93.89 | 2019-2020 | |
| Eisai INC. | $50.08 | 2020 | |
| Allergan, INC. | $47.76 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $44.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.81 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $37.40 | 2019-2020 | |
| Bioventus LLC | $24.58 | 2020 | |
| Arbor Pharmaceuticals, INC. | $23.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.63 | 2020 | |
| Esperion Therapeutics, INC. | $17.06 | 2020 | |
| Sanofi Pasteur INC. | $16.12 | 2019 | |
| Scilex Pharmaceuticals INC. | $15.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$0.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredrick Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.